Geneva, Switzerland and Rockland, MA, May 27, 2004 -- Serono, Inc., the US affiliate of Serono (virt-x: SEO and NYSE: SRA), announced today that the United States Food and Drug Administration (FDA) ...
Merck Serono announced that the FDA has approved EMD Serono‘s GONAL-f RFF Redi-ject (recombinant follitropin alfa) injection, a disposable prefilled drug injector pen indicated for the subcutaneous ...
Gonal-f ® RFF Redi-ject™ (follitropin alfa injection) is indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to ...
The U.S. Food and Drug Administration has approved trospium chloride for the treatment of overactive bladder, a new device that delivers follitropin alpha for infertility, a new indication for ...
GONAL-f (follitropin alfa injection) is a recombinant human follicle-stimulating hormone (r-hFSH) approved for the treatment female infertility and a rare form of male infertility. Merck announced ...
ROCKLAND, Mass., March 22, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced two new real-world data analyses ...
GENEVA, July 4, 2011 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the European Commission (EC) has granted an approval for three pre-filled, ...
ROCKLAND, Mass., Feb. 17, 2022 /PRNewswire/ -- EMD Serono , the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada, announced the launch of its new Slim Pack fertility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results